亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

苯拉唑马布 医学 恶化 哮喘 内科学 嗜酸性粒细胞 美波利祖马布
作者
David J. Jackson,Girolamo Pelaia,Benjamin Emmanuel,Trung Tran,David Cohen,Vivian H. Shih,Anat Shavit,Douglas Arbetter,Rohit Katial,Adrian Rabe,Esther Garcia Gil,Marisa Pardal,Javier Nuevo,M Watt,Silvia Boarino,Sheena Kayaniyil,Cláudia Chaves Loureiro,Alicia Padilla-Galo,Parameswaran Nair
出处
期刊:The European respiratory journal [European Respiratory Society]
卷期号:: 2301521-2301521
标识
DOI:10.1183/13993003.01521-2023
摘要

Pivotal Phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy and safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its real-world effectiveness in SEA according to previous biologic use and key baseline characteristics important for treatment selection.XALOC-1 is a large, multinational, retrospective, observational, real-world study programme of benralizumab in adults with SEA. This 48-week integrated analysis assessed annualised exacerbation rate (AER), maintenance oral corticosteroid (mOCS) use, asthma symptom control and lung function during a 12-month baseline period and up to 48 weeks after benralizumab initiation. Subgroup analyses were based on previous biologic use and key baseline clinical characteristics (mOCS use, blood eosinophil count, exacerbation history, age at asthma diagnosis, fractional exhaled nitric oxide level and presence of atopy and chronic rhinosinusitis with nasal polyps).Of 1002 patients analysed, 380 were biologic-experienced. At Week 48, 71.3% were exacerbation-free (versus 17.2% at baseline); relative reduction in AER was 82.7% overall and 72.9% in biologic-experienced patients; rates were maintained across all key clinical characteristic subgroups. Of patients using mOCS at baseline (n=274), 47.4% (130/274) eliminated their use by Week 48; the mean reduction from baseline in daily dose was 51.2% and, notably, 34.9% in biologic-experienced patients (n=115). Clinically significant improvements in asthma symptom control and lung function were observed.In this large, real-world programme, SEA patients treated with benralizumab had substantial improvements in clinical outcomes irrespective of previous biologic use and key clinical characteristics important to therapeutic decision-making in clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zshjwk18完成签到,获得积分10
36秒前
2分钟前
庾稀发布了新的文献求助10
2分钟前
黄花菜完成签到 ,获得积分10
2分钟前
fev123完成签到,获得积分10
2分钟前
JAJ完成签到 ,获得积分10
5分钟前
清秀的怀蕊完成签到 ,获得积分10
5分钟前
OCDer发布了新的文献求助500
6分钟前
今后应助科研通管家采纳,获得10
7分钟前
寻找土豆的灯完成签到 ,获得积分10
7分钟前
英姑应助科研通管家采纳,获得10
9分钟前
Larock完成签到 ,获得积分10
9分钟前
欣喜雪晴完成签到 ,获得积分10
11分钟前
席康完成签到 ,获得积分10
12分钟前
nianshu完成签到 ,获得积分10
13分钟前
Spring完成签到,获得积分10
17分钟前
传奇3应助guan采纳,获得10
17分钟前
18分钟前
缪静柏发布了新的文献求助10
18分钟前
幽默含莲完成签到,获得积分10
18分钟前
爆米花应助科研通管家采纳,获得10
19分钟前
LQY发布了新的文献求助20
19分钟前
LQY完成签到,获得积分10
19分钟前
20分钟前
guan发布了新的文献求助10
20分钟前
zao完成签到 ,获得积分10
23分钟前
fengfenghao完成签到 ,获得积分10
23分钟前
小辣椒完成签到 ,获得积分10
23分钟前
内向的白玉完成签到 ,获得积分10
23分钟前
肆肆完成签到,获得积分10
24分钟前
moren完成签到 ,获得积分10
24分钟前
斯文败类应助科研通管家采纳,获得10
25分钟前
pinghu完成签到,获得积分10
25分钟前
mengliu完成签到,获得积分10
28分钟前
gk123kk完成签到,获得积分10
29分钟前
30分钟前
py999发布了新的文献求助10
30分钟前
gszy1975完成签到,获得积分10
31分钟前
科研通AI2S应助ektyz采纳,获得10
32分钟前
坚强的广山完成签到,获得积分0
33分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545714
求助须知:如何正确求助?哪些是违规求助? 2175659
关于积分的说明 5600211
捐赠科研通 1896371
什么是DOI,文献DOI怎么找? 946268
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557